Sector

Healthcare

Region

AUM

67.50M

Fund Score

Tema GLP-1, Obesity & Cardiometabolic ETF (NASDAQ:HRTS) Quotes, Forecast and News Summary

Tema GLP-1, Obesity & Cardiometabolic ETF (NASDAQ: HRTS) stock price, news, charts, stock research, profile.

Open	$34.88
High	$35.35
52 Wk High	$36.03
AUM	67.50M
Dividend	-
Ex-Div Date	-
Volume	32.28K
Market Cap	$64.23B
Mgmt Fee	0.99%
P/E Ratio	37.15
Prev. Close	$34.74
Low	$34.88
52 Wk Low	$26.26
Shares Out	-
Yield	-
Div. Freq	-
Avg. Volume Daily	-
Beta	-
Avg. Expense Ratio	0.75%
P/B Ratio	5.29

Recent News

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'

Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.

Piero Cingari

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO

The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.

Piero Cingari

Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply

The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to the growing availability of weight-loss medications.

Benzinga Neuro

FAQ

How do I buy Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) stock?

You can purchase shares of Tema GLP-1, Obesity & Cardiometabolic ETF (NASDAQ:HRTS) through any online brokerage.

View our list of the best stock brokerages

Who are Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) competitors?

There are no as such competitors for Tema GLP-1, Obesity & Cardiometabolic ETF.

What is the forecast, or price target, for Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) stock?

There is no analysis for Tema GLP-1, Obesity & Cardiometabolic ETF to provide a consensus price target.

What is the current price for Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS)?

The stock price for Tema GLP-1, Obesity & Cardiometabolic ETF (NASDAQ: HRTS) is $35.08 last updated August 23, 2024 at 4:15 PM EDT.

Does Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) pay a dividend?

There are no upcoming dividends for Tema GLP-1, Obesity & Cardiometabolic ETF.

When is Tema GLP-1, Obesity & Cardiometabolic ETF (NASDAQ:HRTS) reporting earnings?

Tema GLP-1, Obesity & Cardiometabolic ETF does not have any upcoming earnings scheduled.

Is Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) going to split?

There is no upcoming split for Tema GLP-1, Obesity & Cardiometabolic ETF.

ETF Details

Sector	Healthcare
Category	-
Investment Style	Large Cap Blend
Fund Inception	Nov 20, 2023
Managers	Ryan Houlton Troy Cates Garrett Paolella Yuri Khodjamirian David Song
Definition	-

Investment Policy

The investment seeks to provide long-term growth of capital by investing in companies leading the fight against diabetes, obesity and cardiovascular diseases. Obesity is on the cusp of a revolution in therapeutics, while heart disease, the most common cause of death, is witnessing a renaissance of therapies driven by genetic insights and tools.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'